Chemical characterization, antioxidant, anti-inflammatory and cytotoxic properties of bee venom collected in Northeast Portugal

Filipa Sobral\textsuperscript{a}, Andreia Sampaio\textsuperscript{a}, Soraia Falcão\textsuperscript{a}, Maria João R.P. Queiroz\textsuperscript{b}, Ricardo C. Calhelha\textsuperscript{a,b}, Miguel Vilas-Boas\textsuperscript{a,*}, Isabel C.F.R. Ferreira\textsuperscript{a,*}

\textsuperscript{a}Centro de Investigação de Montanha (CIMO), ESA, Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal.

\textsuperscript{b}Centro de Química da Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal.

* Authors to whom correspondence should be addressed (e-mail: iferreira@ipb.pt telephone +351-273-303219; fax +351-273-325405; e-mail: mvboas@ipb.pt telephone +351-273-303237; fax +351-273-325405).
Abstract

Bee venom (BV) or apitoxin is a complex mixture of substances with reported biological activity. In the present work, five bee venom samples obtained from *Apis mellifera iberiensis* from the Northeast Portugal (two different apiaries) were chemically characterized and evaluated for their antioxidant, anti-inflammatory and cytotoxic properties. The LC/DAD/ESI-MS analysis of the samples showed that melittin was the most abundant compound, followed by phospholipase A2 and apamin. All the samples revealed antioxidant and anti-inflammatory activity but without a direct relation with any of the individual chemical components identified. The results highlight that there are specific concentrations (present in BV5) in which these compounds are more active. The BV samples showed similar cytotoxicity for all the tested tumour cell lines (MCF-7, NCI-H460, HeLa and HepG2), being MCF-7 and HeLa the most susceptible ones. Nevertheless, the studied samples seem to be suitable to treat breast, hepatocellular and cervical carcinoma because at the active concentrations, the samples were not toxic for non-tumour cells (PLP2). Regarding the non-small cell lung carcinoma, BV should be used under the toxic concentration for non-tumour cells. Overall, the present study corroborates the enormous bioactive potential of BV being the first report on samples from Portugal.

**Keywords:** Bee venom; apamin; melittin; phospholipase A2; antioxidant/anti-inflammatory; cytotoxic
1. Introduction

Bee venom (BV) or apitoxin, produced in the venom gland of the bee (*Apis mellifera*), located in the abdominal cavity, is a complex mixture of substances with reported biological activity (Liu et al., 2002; Oršolić, 2009; Oršolić, 2012). The active compounds of the BV have been described as proteins and peptides (melittin (MEL), apamin (APA), adolapin, the mast cell degranulating peptide, secapin, procamine, protease inhibitor, tertiapin and other small peptides), enzymes (phospholipase A2 (PLA2), hyaluronidase, acid phosphomonoesterase, lysophospholipase and α-glucosidase), as well as non-peptide components, such as physiologically active amines (histamine, dopamine and noradrenalin), amino acids (aminobutyric acid and α-amino acids), sugars (glucose and fructose), phospholipids and volatile compounds (Park et al., 2010; Gajski and Garaj-Vrhovac, 2013; Liu et al., 2014). Within these mixture, the major components of BV are histamine, catecholamines, polyamines, melittin and PLA2 (Oršolić et al., 2003).

BV has been used as a traditional medicine to treat chronic inflammatory (arthritis, rheumatism and back pain) (Chang and Bliven, 1979; Kwon et al., 2001; Kim et al., 2003; Son et al., 2007; Park et al., 2008; Vasileiadou et al., 2010) and skin (Escrig et al., 1997; Han et al., 2012) diseases. In fact, the anti-inflammatory properties of BV samples from different origins such as Egypt (Amin and Abdel-Raheem, 2014), Korea (Park et al., 2007; Park et al., 2008; Lee et al., 2009), USA (Chang and Bliven, 1979) and even commercial samples (Jang et al., 2005; Moon et al., 2007; Yoon et al., 2008) have been reported in apitherapy. Furthermore, BV individual compounds have also shown the same properties, as in the case of mast cell degranulating peptide (Banks et al., 1990), MEL (Moon et al., 2006; Park et al., 2007; Srivastava et al., 2012; Rayahin et al., 2014) and PLA2 (Ximenes et al., 2012), which are related with their capacity to reduce pro-inflammatory cytokines such as tumor necrosis factor (TNF-α) and interleukins (IL-
1β, or IL-6), as well as other inflammatory mediators including prostaglandin E2 (PGE2) and nitric oxide (NO), which are synthesized by cyclooxygenase (COX) and inducible nitric oxide synthase (iNOS), respectively. The production of these mediators has been demonstrated in several inflamed tissues involved in the pathogenesis of several diseases, such as atherosclerosis, obesity, metabolic syndrome, diabetes, neurodegenerative diseases, and several types of cancers (Nam et al., 2003; Jang et al., 2005; Janik et al., 2007; Karimzadeh et al., 2013; Mohammadi et al., 2015).

The anticancer effects of commercial BV (Xiu et al., 2002; Moon et al., 2006; Lee et al., 2007; Gajski et al., 2014; Kim et al., 2015), BV samples from Iran (Alizadehnohi et al., 2012) and Slovenia (Oršolić et al., 2003; Oršolić, 2009) and individual components such as PLA2 (Ferguson and Duncan, 2009) and MEL (Hu et al., 2006; Huh et al., 2012) have also been described. These properties are related with induction of apoptosis and necrosis (Liu et al., 2014) and cytotoxic effects in different types of cell lines, including prostate, breast, kidney, bronchial epithelium (Huh et al., 2012), lung (Putz et al., 2006), ovarian (Alizadehnohi et al., 2012), colon (Ferguson and Duncan, 2009), bladder (Ip et al., 2012), leukemic (Moon et al., 2006), cervical (Oršolić et al., 2009; Gajski and Garaj-Vrhovac, 2013; Gajski et al., 2014) and laryngeal carcinoma (Gajski and Garaj-Vrhovac, 2013), but also in non-tumor cells such as lymphocytes (Lee et al., 2007; Garaj-Vrhovac and Gajski, 2009).

Antimutagenic (Varanda et al., 1999), antinociceptive (Baek et al., 2006), and radioprotective (Garaj-Vrhovac and Gajski, 2009) effects are among other bioactive properties of BV, together with the low explored antioxidant potential of this natural matrix. A few studies report the antioxidant effects of BV samples from Korea (Han et al., 2010) and USA (Rekka et al., 1990), and of PLA2 (Snyder et al., 1985).
In the present work, five bee venom samples obtained from *Apis mellifera iberiensis* from the Northeast Portugal were chemically characterized and evaluated for their antioxidant, anti-inflammatory and cytotoxic properties.

2. Materials and methods

2.1. Samples collection

Five distinct bee venom samples were collected between May and July of 2014 from *Apis mellifera iberiensis* hives located in two different apiaries near Bragança (BV1-5), in the Northeast region of Portugal. The physical distance between the two apiaries (BV1-4 in “Milhão” (41º47’39” N; 6º39’10” W); BV5 in “Aveleda” (41º54’9” N; 6º40’2” W)) is about 12 Km. For the sample collection a BeeWhisper 0412 bee venom collector (IGK Electronics, Bulgaria) was placed at the entrance of the hive. When the honeybees covered the entire surface of the collector frame and came into contact with the wire grid, a mild electrical impulse shock (1.8 V) was applied. The immediate response of the honeybees was generated, and they stung the surface of the collector glass. Every 50 seconds, the device paused for additional 10 seconds. After 40 minutes of working time, the device turned off automatically. That was the maximum time applied for bee venom collection, per colony, in one session. Each sample corresponds to bee venom collected from 5 neighbor colonies. After the collection period, the bee venom was scraped off from the glass with a sharp scraper. The bee venom was then freeze-dried and stored at -18 °C until further analysis.

2.2. Standards and reagents
Apamin from bee venom (purity 98.3%) was obtained from CalBiochem (San Diego, CA, USA). Phospholipase A2 from bee venom (activity: 1775 units mg\(^{-1}\) solid), cytochrome \(c\) from equine heart (purity \(\geq 95\%\)), trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), lipopolysaccharide (LPS), dexamethasone, sulforhodamine B, trypan blue, trichloro acetic acid (TCA) and Tris were purchased from Sigma-Aldrich (St. Louis, MO, USA). Melittin from bee venom (purity: 67%) was obtained from Latoxin (Valence, France). Formic acid was from Panreac (Barcelona, Spain), while HPLC grade acetonitrile was from Fisher Scientific UK (Loughborough, Leics, UK). 2,2-Diphenyl-1-picrylhydrazyl (DPPH) was obtained from Alfa Aesar (Ward Hill, USA). RAW 264.7 cells were purchased from ECACC (“European Collection of Animal Cell Culture”) (Salisbury, UK) and DMEM from Hyclone (Logan, Utah, US). The Griess Reagent System Kit was purchased from Promega (Madison, WI, USA). Dulbecco’s modified Eagle’s medium (DMEM), hank’s balanced salt solution (HBSS), fetal bovine serum (FBS), L-glutamine, trypsin-EDTA, penicillin/streptomycin solution (100 U/mL and 100 mg/mL, respectively) were purchased from Gibco Invitrogen Life Technologies (California, USA). Water was treated in a Milli-Q water purification system (TGI Pure Water Systems, USA).

2.3. Chemical characterization of the samples by LC/DAD/ESI-MS\(^n\)

The LC/DAD/ESI-MS\(^n\) analyses were performed on a Dionex Ultimate 3000 UPLC instrument (Thermo Scientific, USA) equipped with a diode-array detector and coupled to a mass detector. The chromatographic system consisted of a quaternary pump, an autosampler maintained at 5 °C, a degasser, a photodiode-array detector, an automatic thermostatic column compartment. The chromatographic separation was carried out according with previously described work with some modifications on a XSelect CSH130 C18, 100mm\(\times\)2.1 mm id, 2.5 \(\mu\)m XP column (Waters,
Milford, MA) and its temperature was maintained at 30 ºC. The mobile phase consisted of (A) 0.1% (v/v) formic acid in water and (B) 0.1% (v/v) formic acid in acetonitrile, which were previously degassed and filtrated. The solvent gradient started with 100% A, reaching 60% B at 12 min, 100% B at 15 min and return to the initial conditions. The flow rate was 0.3 mL/min, with an injection volume of 40 µL. Spectral data for all peaks were accumulated in the range 190–500 nm. Cytochrome c, as the internal standard (IS), was prepared in deionized water at the concentration of 25 µg/mL. For the analysis, the lyophilized bee venom (3 mg) was dissolved in 10 mL of internal standard. Each sample was filtered through a 0.2 µm nylon membrane (Whatman). Bee venom quantification was achieved using calibration curves for apamin (2-60 µg/mL; y = 0.032x+0.012), phospholipase A2 (4-120 µg/mL; y = 0.042x+0.045), melittin (21-335 µg/mL; y = 0.032x+0.133). The standard solutions were prepared by dissolving them in IS solution for the desire concentration.

The mass spectrometer was operated in the positive ion mode using Linear Ion Trap LTQ XL mass spectrometer (Thermo Scientific, San Jose, CA, USA) equipped with an ESI source. Typical ESI conditions were nitrogen sheath gas 35 psi, spray voltage 3.5 kV, source temperature 300 ºC, capillary voltage 20 V, and the tube lens offset was kept at voltage of 74 V. The full scan covered the mass range from m/z 50 to 2000. The collision energy used was 30 (arbitrary units). Data acquisition was carried out with Xcalibur® data system (Thermo Scientific, San Jose, CA, USA).

2.4. Evaluation of antioxidant properties

The BV samples were dissolved in water at 5 mg/mL and then submitted to further dilutions from 5 to 0.02 mg/mL. DPPH radical-scavenging activity was evaluated by using an ELX800
microplate reader (Bio-Tek Instruments, Inc; Winooski, VT, USA), and calculated as a percentage of DPPH discolouration using the formula: \( [(A_{DPPH} - A_S) / A_{DPPH}] \times 100 \), where \( A_S \) is the absorbance of the solution containing the sample at 515 nm, and \( A_{DPPH} \) is the absorbance of the DPPH solution. Reducing power was evaluated by the capacity to convert \( \text{Fe}^{3+} \) into \( \text{Fe}^{2+} \), measuring the absorbance at 690 nm in the microplate reader mentioned above. Inhibition of \( \beta \)-carotene bleaching was evaluated though the \( \beta \)-carotene/linoleate assay; the neutralization of linoleate free radicals avoids \( \beta \)-carotene bleaching, which is measured by the formula: \( \beta \)-carotene absorbance after 2h of assay/initial absorbance) \( \times 100 \). Lipid peroxidation inhibition in porcine (\( Sus scrofa \)) brain homogenates was evaluated by the decreasing in thiobarbituric acid reactive substances (TBARS); the colour intensity of the malondialdehyde-thiobarbituric acid (MDA-TBA) was measured by its absorbance at 532 nm; the inhibition ratio (%) was calculated using the following formula: \( [(A - B) / A] \times 100\% \), where A and B were the absorbance of the control and the sample solution, respectively (Fernandes et al., 2013). The results were expressed in EC\(_{50}\) values (sample concentration providing 50% of antioxidant activity or 0.5 of absorbance in the reducing power assay). Trolox was used as positive control.

2.5. Evaluation of anti-inflammatory properties

The BV samples were dissolved in water at 4 mg/mL and then submitted to further dilutions from 4 to 0.0625 mg/mL. The mouse macrophage-like cell line RAW264.7 was cultured in DMEM medium supplemented with 10% heat-inactivated foetal bovine serum and glutamine at 37°C under 5% CO\(_2\), in humidified air. For each experiment, cells were detached with a cell scraper. Under our experimental cell density (\( 5 \times 10^5 \) cells/mL), the proportion of dead cells was less than 1%, according to Trypan blue dye exclusion tests. Cells were seeded in 96-well plates
at 150,000 cells/well and allowed do attach to the plate overnight. Then, cells were treated with the different concentrations of each of the extracts for 1 h. Dexamethasone (50 µM) was used as a positive control for the experiment. The following step was stimulation with LPS (1 µg/mL) for 18 h. The effect of the tested samples in the absence of LPS was also evaluated, in order to observe if they induced changes in NO basal levels. In negative controls, no LPS was added. Both extracts and LPS were dissolved in supplemented DMEM. For the determination of nitric oxide, a Griess Reagent System kit was used, which contains sulfanilamide, NED and nitrite solutions. The cell culture supernatant (100 µL) was transferred to the plate in duplicate and mixed with sulfanilamide and NED solutions, 5-10 minutes each, at room temperature. The nitrite produced was determined by measuring the optical density at 515 nm, in the microplate reader referred above, and was compared to the standard calibration curve.

The results were expressed in percentages of inhibition of NO production in comparison with the negative control (100%) and EC$_{50}$ values (sample concentration providing 50% of inhibition of NO production) were also estimated.

2.6. Evaluation of cytotoxic properties

The BV samples were dissolved in water at 4 mg/mL and then submitted to further dilutions from 4 to 0.0625 mg/mL. Four human tumor cell lines were used: MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), HeLa (cervical carcinoma) and HepG2 (hepatocellular carcinoma). Cells were routinely maintained as adherent cell cultures in RPMI-1640 medium containing 10% heat-inactivated FBS and 2 mM glutamine (MCF-7, NCI-H460 HeLa and HepG2 cells), at 37 °C, in a humidified air incubator containing 5% CO$_2$. Each cell line was plated at an appropriate density (7.5 × 10$^3$ cells/well for MCF-7 and NCI-H460 or
1.0 × 10^4 cells/well for HeLa and HepG2) in 96-well plates. Sulforhodamine B assay was performed according to a procedure previously described by the authors (Barros et al., 2013). For evaluation of the cytotoxicity in non-tumor cells, a cell culture was prepared from a freshly harvested porcine liver obtained from a local slaughterhouse, according to a procedure established by the authors (Abreu et al., 2011); it was designed as PLP2. Cultivation of the cells was continued with direct monitoring every two to three days using a phase contrast microscope. Before confluence was reached, cells were subcultured and plated in 96-well plates at a density of 1.0×10^4 cells/well, in DMEM medium with 10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. Ellipticine was used as positive control and the results were expressed in GI_{50} values (concentration that inhibited 50% of the net cell growth).

2.7. Statistical analysis

For all the experiments three samples were analyzed and all the assays were carried out in triplicate. The results are expressed as mean values ± standard deviation (SD). The differences between the different samples were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s honestly significant difference post hoc test with α = 0.05, coupled with Welch’s statistic. This procedure was carried out using SPSS v. 22.0 program.
3. Results and discussion

The chemical components identified in the five studied BV samples are presented in Table 1. Melittin was the most abundant compound in all the samples, while apamin was the component at the lowest concentration (Table 1, Fig. 1). In fact, mellitin has been reported by different authors as the main constituent of BV (Park et al., 2012; Cho et al., 2013). BV2 gave the highest levels of mellitin (86.72 ± 0.50 µg/mL), phospholipase A2 (11.36 ± 0.18 µg/mL) and apamin (1.80 ± 0.03 µg/mL), followed by BV4. On the other hand, BV5 and, mainly, BV1 showed the lowest concentrations in all the compounds. Although the individual amount changes with the samples, it is evident that the proportion of each compound, normalized to the overall mass, is similar, with mellitin, phospholipase A2 and apamin representing, in all samples, 86%, 13% and 2%, respectively. This stresses out that the presence of other substances in the overall mass of the bee venom varies for each sample. Additionally, samples BV1 and BV5 were both collected earlier in May, which corresponds to the beginning of the production season. This feature may influence the age of the honeybees, and therefore the apitoxin composition, since it is well known that the synthesis and composition of bee venom is age dependent, with lower melittin content found in younger bees (Dong et al., 2015).

All the samples revealed antioxidant and anti-inflammatory activity and, apparently, not related to none of the individual components identified and quantified in the samples. BV5 proved to have the highest free radicals scavenging activity, reducing power, lipid peroxidation inhibition and also the highest capacity to inhibit NO production (Table 2). Among the studied BV samples, BV5 was the unique that was collected in a different apiary. It should be highlighted that the anti-inflammatory activity of all BV samples (EC50 values < 8 µg/mL) was higher than the positive control, dexamethasone (EC50 value=15.5±1.96 µg/mL; Table 2).
The lack of correlations between the concentration of mellitin, phospholipase A2 or apamin, and the results of the in vitro antioxidant and anti-inflammatory activities evidences that there are specific concentrations in which these compounds are more active. At higher or lower concentrations, the mentioned activities decrease probably due to antagonistic effects. Curiously, a pro-inflammatory effect of samples in BV3, BV4 and BV5 was observed at the lowest tested concentration (increase in the NO levels in comparison with the negative control (>100% at 1 µg/mL; Figure 2). To our knowledge this kind of effect was not previously reported, being only described the inhibition of NO formation in Raw 264.7 cells by BV samples in the range of 0.1-2 µg/mL (Lee et al., 2009), 0.5-2 µg/mL (Moon et al., 2007), 0.5-5 µg/mL (Park et al., 2007) and 1-20 µg/mL (Jang et al., 2005), as in the present study (tested concentrations: 1-15 µg/mL). In vivo experiments with Lewis rats also support the anti-inflammatory effects of BV samples (Chang and Bliven, 1979; Amin and Abdel-Raheem, 2014). Regarding the antioxidant effects of BV samples, they have been related with the capacity to inhibit the lipid peroxidation process (Rekka et al., 1990) and to increase superoxide dismutase (SOD) activity (Han et al., 2010).

The studied BV samples showed similar cytotoxicity for all the tested tumour cell lines: breast (MCF-7), non-small cell lung (NCI-H460), cervical (HeLa) and HepG2 (hepatocellular) carcinoma (Table 3). MCF-7 and HeLa were the most susceptible cell lines to the action of BV samples (GI50 values < 5 µg/mL). In the case of HeLa cell line, a GI50 value in the same magnitude was reported by Orsolić (2009) for BV from Slovenia (3 µg/mL). Otherwise, commercial BV samples revealed lower activity against HeLa cells (GI50=9.7 µg/mL (Kim et al., 2015) and ~20% of cellular viability at 60 µg/mL (Gajski et al., 2014). The antitumor effects of BV samples were also demonstrated by in vivo experiments (Liu et al., 2002; Oršolić, 2003).
It should be highlighted that despite the toxicity observed for BV samples in relation to non-tumour liver cells (PLP2; Table 3), at the GI₅₀ concentrations obtained for tumour cell lines, none of the samples was toxic for PLP2, except for the case of NCI-H460 in which the cytotoxic concentrations (GI₅₀ values between 16.00 ± 2.34 and 19.68± 1.80 µg/mL) were higher than the ones observed in PLP2 (GI₅₀ values between 10.11 ± 0.91 and 15.03 ± 0.28 µg/mL). Therefore, the studied samples seem to be suitable to treat breast, hepatocellular and cervical carcinoma, and regarding the non-small cell lung carcinoma, it should be used under the concentration toxic for non-tumour cells. The toxicity of BV for non-tumour cells, such as lymphocytes was also previously reported by different authors (Gajski and Garaj-Vrhovac, 2008; Garaj-Vrhovac and Gajski, 2008; Mohammadi et al., 2015).

4. Conclusions

Overall, this study demonstrates the broad bioactive potential of BV including antioxidant, anti-inflammatory and cytotoxic activities, being the first report for Portuguese samples. Despite the identification of the most abundant molecules in BV, some other minor compounds, together with synergistic/antagonistic effects at specific concentrations, could be involved in the reported bioactivities, contributing to different results among BV samples.

Acknowledgments

The authors are grateful to the Foundation for Science and Technology (FCT, Portugal) for financial support to CIMO (PEst-OE/AGR/UI0690/2014) and R.C. Calhelha grant (SFRH/BPD/68344/2010).
References


Figure captions

**Fig. 1.** Representative chromatographic profile at 220 nm of *A. mellifera iberiensis* venom: 1- apamin; 2- phospholipase A2; IS- internal standard (cytochrome C, 25 µg/mL); 3- melittin.

**Fig. 2.** Nitric oxide production as function of concentration of *A. mellifera iberiensis* venom (BV1-5). As the production of oxide nitric is proportional to the inflammatory process, a decrease in the nitric oxide concentration corresponds to potential anti-inflammatory activity.
Table 1

Chemical characterization of the bee venom (BV) samples by LC/DAD/ESI-MS\textsuperscript{n} analysis.

<table>
<thead>
<tr>
<th></th>
<th>BV 1</th>
<th>BV 2</th>
<th>BV 3</th>
<th>BV 4</th>
<th>BV 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apamin (µg/mL)</td>
<td>0.94±0.01\textsuperscript{d}</td>
<td>1.80±0.03\textsuperscript{ab}</td>
<td>1.61±0.17\textsuperscript{b}</td>
<td>1.95±0.02\textsuperscript{a}</td>
<td>1.25±0.04\textsuperscript{c}</td>
</tr>
<tr>
<td>Phospholipase A2 (µg/mL)</td>
<td>4.98±0.01\textsuperscript{d}</td>
<td>11.36±0.18\textsuperscript{a}</td>
<td>9.02±0.62\textsuperscript{c}</td>
<td>10.08±0.34\textsuperscript{b}</td>
<td>5.98±0.11\textsuperscript{d}</td>
</tr>
<tr>
<td>Melittin(µg/mL)</td>
<td>35.64±0.09\textsuperscript{e}</td>
<td>86.72±0.50\textsuperscript{a}</td>
<td>70.58±3.99\textsuperscript{c}</td>
<td>80.74±0.34\textsuperscript{b}</td>
<td>52.20±0.66\textsuperscript{d}</td>
</tr>
</tbody>
</table>

In each row different letters mean significant differences between samples (p<0.05).
Table 2

*In vitro* antioxidant and anti-inflammatory activities of the bee venom (BV) samples.

<table>
<thead>
<tr>
<th></th>
<th>BV 1</th>
<th>BV 2</th>
<th>BV 3</th>
<th>BV 4</th>
<th>BV 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antioxidant activity (EC$_{50}$ values, µg/mL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPPH scavenging activity</td>
<td>487±7$^b$</td>
<td>451±6$^c$</td>
<td>491±1$^b$</td>
<td>512±16$^a$</td>
<td>346±4$^d$</td>
</tr>
<tr>
<td>Reducing power</td>
<td>326±16$^a$</td>
<td>238±10$^d$</td>
<td>306±1$^b$</td>
<td>291±2$^c$</td>
<td>225±5$^e$</td>
</tr>
<tr>
<td>β-carotene bleaching inhibition</td>
<td>710±10$^b$</td>
<td>545±9$^d$</td>
<td>826±9$^a$</td>
<td>666±23$^c$</td>
<td>435±15$^e$</td>
</tr>
<tr>
<td>TBARS inhibition</td>
<td>1.45±0.08$^c$</td>
<td>1.22±0.05$^d$</td>
<td>2.38±0.20$^a$</td>
<td>1.70±0.03$^b$</td>
<td>1.07±0.10$^e$</td>
</tr>
<tr>
<td><strong>Anti-inflammatory activity (EC$_{50}$ values, µg/mL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO production</td>
<td>6.77±0.13$^b$</td>
<td>5.76±0.06$^c$</td>
<td>5.81±0.94$^c$</td>
<td>7.91±0.17$^a$</td>
<td>4.85±0.02$^d$</td>
</tr>
</tbody>
</table>

EC$_{50}$ values for antioxidant activity: sample concentration providing 50% of antioxidant activity or 0.5 of absorbance in the reducing power. Trolox EC$_{50}$ values: 41 µg/mL (reducing power), 42 µg/mL (DPPH scavenging activity), 18 µg/mL (β-carotene bleaching inhibition) and 23 µg/mL (TBARS inhibition).

EC$_{50}$ values for anti-inflammatory activity: sample concentration providing 50% of inhibition of the NO production in relation to negative control (100%). Dexamethasone EC$_{50}$ value: 15.5±1.96 µg/mL.

In each row different letters mean significant differences between samples (p<0.05).
Table 3

*In vitro* cytotoxic activity of the bee venom (BV) samples.

<table>
<thead>
<tr>
<th></th>
<th>BV 1</th>
<th>BV 2</th>
<th>BV 3</th>
<th>BV 4</th>
<th>BV 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>For human tumour cell lines (GI&lt;sub&gt;50&lt;/sub&gt; values, µg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCF-7 (breast carcinoma)</td>
<td>4.16±0.49&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.44±0.43&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.02±0.38&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.51±0.21&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.49±0.42&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>NCI-H460 (non-small cell lung carcinoma)</td>
<td>16.00±2.34&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17.68±0.53&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.18±0.86&lt;sup&gt;a&lt;/sup&gt;</td>
<td>19.68±1.80&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17.98±0.86&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HeLa (cervical carcinoma)</td>
<td>4.54±0.22&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>2.83±0.41&lt;sup&gt;c&lt;/sup&gt;</td>
<td>4.41±0.01&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>3.51±0.81&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>4.80±0.15&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HepG2 (hepatocellular carcinoma)</td>
<td>10.6±1.89&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.19±1.40&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>5.43±0.08&lt;sup&gt;c&lt;/sup&gt;</td>
<td>6.55±0.11&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>9.85±0.36&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>For non-tumor liver cells (GI&lt;sub&gt;50&lt;/sub&gt; values, µg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLP2</td>
<td>15.03±0.28&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13.86±0.10&lt;sup&gt;b&lt;/sup&gt;</td>
<td>10.11±0.91&lt;sup&gt;b&lt;/sup&gt;</td>
<td>12.94±1.21&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>14.66±0.66&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

GI<sub>50</sub> values: sample concentration achieving 50% of growth inhibition in human tumour cell lines or in liver primary culture PLP2. Ellipticine GI<sub>50</sub> values: 1.21 µg/mL (MCF-7), 1.03 µg/mL (NCI-H460), 0.91 µg/mL (HeLa), 1.10 µg/mL (HepG2) and 2.29 µg/mL (PLP2).

In each row different letters mean significant statistical differences along shelf life (*p*<0.05).
Fig. 1.
Fig. 2.